IN8bio, Inc. presented preclinical data for its CD19‑targeted pan‑gamma‑delta T cell engager INB‑619 at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago (Abstract 2132100). The data demonstrated complete elimination of B cells in both healthy and active systemic lupus erythematosus (SLE) donor models, with efficacy comparable to FDA‑approved CD19 and CD20 engagers blinatumomab and mosunetuzumab. IL‑6 secretion was reported to be multiple times lower than that observed with the marketed compounds.
INB‑619 selectively expands Vδ1+ and Vδ2+ gamma‑delta T cells without activating CD4+ or CD8+ αβ T cells, a profile that may reduce the risk of cytokine release syndrome and other immune‑related toxicities. The company highlighted that this selective expansion could enable higher dosing and durable immune reset in autoimmune diseases such as SLE, positioning INB‑619 as a first‑in‑class therapy.
IN8bio plans to file an Investigational New Drug application and initiate a Phase 1/2 clinical trial in SLE patients later in 2026. The company noted that while preclinical results are promising, translation to human therapy remains uncertain and further studies are required. The SLE market, which serves approximately 1.5 million Americans, currently relies on therapies such as belimumab and rituximab, underscoring the potential impact of a novel, safer B‑cell depletion strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.